Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Amit Sanyal, MD: A Clinician’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Apr

Today In Oncology

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos